Mylan Pharmaceuticals

Compiled by PlainTrial · August 8, 2026

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Mylan Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#191 of 15,742 sponsors by registered trial count).

146 total trials 1 currently recruiting 143 completed early-phase tilt top decile by trial count

Mylan Pharmaceuticals: 146 sponsored US clinical trials, 1 recruiting.

Mylan Pharmaceuticals sponsors 146 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 143 completed. 3 of these trials are in Phase 3-4 (later-stage) and 143 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 35 trials.

Mylan Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#191 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

B 87/100

143 of 145 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (98.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

146 total, page 2 of 3

Mylan Pharmaceuticals

Top-decile sponsor footprint

Open and recent trials

Food Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg

Fasting Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg

Food Study of Valacyclovir Hydrochloride Tablets 1000 mg to Valtrex® Tablets 1000 mg

Fasting Study of Valacyclovir Hydrochloride Tablets 1000 mg and Valtrex® Tablets 1000 mg

Fed Study of Azithromycin Tablets 600 mg to Zithromax® Tablets 600 mg

Fasting Study of Azithromycin Tablets 600 mg to Zithromax® Tablets 600 mg

Food Study of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg to Paxil CR™ Tablets 25 mg

Fasting Study of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg to Paxil CR™ Tablets 25 mg

Fasting Study of Alprazolam Extended-Release Tablets 1 mg to Xanax XR Tablets 1 mg

Fasting Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg

Food Study of Divalproex Sodium Extended-Release Tablets 500 mg to Depakote ER® Tablets 500 mg

Food Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg

Fasting Study of Lorazepam Tablets 2 mg and Ativan Tablets 2 mg

Fasting Study of Divalproex Sodium Extended-Release Tablets 500 mg to Depakote ER® Tablets 500 mg

Fasting Study of Sumatriptan Succinate Tablets 100 mg to Imitrex® Tablets 100 mg

Food Study of Glimepiride Tablets 1 mg to Amaryl® Tablets 1 mg

Food Study of Sumatriptan Succinate Tablets 100 mg to Imitrex® Tablets 100 mg

Fasting Study of Glimepiride Tablets 1 mg to Amaryl® Tablets 1 mg

Fed Study of Finasteride Tablets 5 mg and Proscar® Tablets 5 mg

Fasting Study of Finasteride Tablets 5 mg and Proscar Tablets 5 mg

Food Study of Escitalopram Oxalate Tablets 20 mg to Lexapro® Tablets 20 mg

Food Study of Lamotrigine Tablets 25 mg to Lamictal® Tablets 25 mg

Fasting Study of Alprazolam Extended-Release Tablets 3 mg to Xanax XR® Tablets 3 mg

Food Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mg

Fasting Study of Escitalopram Oxalate Tablets 20 mg and Lexapro® Tablets 20 mg

Fed Study of Alprazolam Extended-release Tablets 3 mg to Xanax XR® Tablets 3 mg

Fasting Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mg

Fasting Study of Lamotrigine Tablets 25 mg to Lamictal® Tablets 25 mg

Fasting Study of Balsalazide Disodium Capsules 750 mg and Colazal® Capsules 750 mg

Fasting Study of Amlodipine and Benazepril HCl Capsules 10 mg/20 mg to Lotrel® Capsules 10 mg/20 mg

Fed Study of Amlodipine and Benazepril HCl Capsules 10 mg/20 mg to Lotrel® Capsules 10 mg/20 mg

Fed Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg

Fasting Study of Cilostazol Tablets 100 mg and Pletal® Tablets 100 mg

Fasting Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg

Fasting BE Study of Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR Tablets 500 mg

Food BE Study Metformin Hydrochloride ER Tablets 500 mg and Glucophage XR 500 mg

Fed Study of Terbinafine Hydrochloride Tablets 250 mg and Lamisil® 250 mg

Fasting Study of Terbinafine Hydrochloride Tablets 250 mg and Lamisil® Tablets 250 mg

Fasting Study of Metolazone Tablets 10 mg and Zaroloxyn® Tablets 10 mg

Fasting Study of Metformin Hydrochloride ER Tablets 750 mg and Glucophage® XR Tablets 750 mg

Food Study Metformin Hydrochloride ER Tablets 750 mg and Glucophage XR 750 mg

Fed Study of Zonisamide Capsules 100 mg and Zonegran® Capsules 100 mg

Food Study of Fexofenadine Tablets 180 mg and Allegra® Tablets 180 mg

Fasting Study of Mercaptopurine 50 mg and Purinethol® Tablets 50 mg

Fasting Study of Zonisamide Capsules 100 mg and Zonegran® Capsules 100 mg

Fasting Study of Fexofenadine Tablets 180 mg and Allegra® Tablets 180 mg

Fasting Study of Metolazone Tablets 5 mg and Zaroloxyn® Tablets 5 mg

Food Study of Nitrofurantoin Macrocrystals 100 mg Capsules and Macrodantin® 100 mg

Fasting Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg

Food Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg

Phase Distribution

Therapeutic Areas

What is open in the Mylan Pharmaceuticals pipeline

Mylan Pharmaceuticals: open-pipeline peers nationwide

Sponsors near 146 trials (± recruiting share)

Sponsors near 1% open enrollment (± trial volume)

Related